| 刘冬英，李艳文，刘裕杰.安罗替尼三线治疗非小细胞肺癌脑转移患者的效果[J].中国医药科学,2022,(20):150-153 基金项目:广东省江门市医疗卫生科技计划项目（2019A010） |
| 安罗替尼三线治疗非小细胞肺癌脑转移患者的效果 |
| Effect of anlotinib as a third-line therapy in non-small-cell lung cancer patients with brain metastases |
| |
| DOI： |
| 中文关键词: 安罗替尼；非小细胞肺癌；脑转移；三线治疗 |
| 英文关键词:Anlotinib; Non-small-cell lung cancer; Brain metastases; Third-line therapy |
| 作者 | 单位 | | 刘冬英，李艳文，刘裕杰 | 广东省江门市中心医院肿瘤科，广东江门 529030 |
|
| 摘要点击次数: 224 |
| 全文下载次数: 415 |
| 中文摘要: |
| [摘要] 目的 探索安罗替尼三线治疗非小细胞肺癌（NSCLC）脑转移患者的效果。 方法 选取江门市中心医院肿瘤科2019年3月1日至2021年2月28日就诊的经过两种或两种以上系统化疗或靶向治疗失败的晚期NSCLC伴脑转移患者为研究对象，分为对照组（n=30）和观察组（n=30）。对照组行全脑放射治疗；观察组采用全脑放射治疗联合安罗替尼。安罗替尼至少服用3个周期，每3个周期复查CT及MRI，采用RECIST标准评价疗效，比较两组患者的疗效、颅内无进展生存期和总生存期。比较治疗前后患者的生活状态和血清血管内皮生长因子（VEGF）水平；评价观察组患者的毒副反应。 结果 观察组客观缓解率（ORR）、疾病控制率（DCR）均高于对照组，差异有统计学意义（P < 0.05）。观察组颅内无进展生存期（iPFS）、总生存期（OS）均比对照组长，差异有统计学意义（P < 0.05）。治疗后观察组卡式功能状态评分（KPS）高于对照组，差异有统计学意义（P < 0.05）。治疗后观察组血清VEGF水平低于对照组，差异有统计学意义（P < 0.05）。观察组毒副反应可耐受。 结论 安罗替尼三线治疗NSCLC脑转移能有效延长患者的iPFS和OS，降低血清VEGF水平，改善患者生活质量，安全性良好，具有较高的推广价值。 |
| 英文摘要: |
| [Abstract] Objective To explore the efficacy of anlotinib as a third-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases. Methods Patients who visited the Department of Oncology of Jiangmen Central Hospital from March 1, 2019 to February 28, 2021 and failed two or more prior systemic chemotherapies or targeted therapy for advanced NSCLC with brain metastasis were selected as the study subjects. They were divided into the control group(n=30) and the observation group(n=30). The control group was treated with whole brain radiotherapy. Patients in the observation group were treated with whole-brain radiation therapy combined with anlotinib. The patients in the observation group received anlotinib for at least three cycles, and the CT and MRI were reexamined in both groups every three cycles. The RECIST criteria was adopted for efficacy evaluation. The efficacy, intracranial progression-free survival (iPFS) and overall survival (OS) were compared between the two groups. The quality of life and level of serum vascular endothelial growth factor (VEGF) before and after treatment were compared. The toxicities and side effects of the observation group were evaluated. Results The objective response rate(ORR) and disease control rate(DCR) in the observation group were higher than those in the control group, with statistically significant differences (P < 0.05). The iPFS and OS of the observation group were longer than those of the control group, with statistically significant differences (P < 0.05). After treatment, the score of Karnofsky Performance Status (KPS) of the observation group was higher than that of the control group, with statistically significant difference (P < 0.05). After treatment, the level of VEGF in the observation group was lower than that in the control group, with statistically significant difference (P < 0.05). The toxicities and side effects in the observation group were tolerable. Conclusion Anlotinib as a third-line therapy in NSCLC patients with brain metastasis can effectively prolong the iPFS and the OS, reduce serum VEGF level and improve the quality of life of patients, with good safety. Therefore, it has high promotional value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)